Surveillance of carbapenem-resistant organisms using next-generation sequencing

Front Public Health. 2023 May 15:11:1184045. doi: 10.3389/fpubh.2023.1184045. eCollection 2023.

Abstract

The genomic data generated from next-generation sequencing (NGS) provides nucleotide-level resolution of bacterial genomes which is critical for disease surveillance and the implementation of prevention strategies to interrupt the spread of antimicrobial resistance (AMR) bacteria. Infection with AMR bacteria, including Gram-negative Carbapenem-Resistant Organisms (CRO), may be acute and recurrent-once they have colonized a patient, they are notoriously difficult to eradicate. Through phylogenetic tools that assess the single nucleotide polymorphisms (SNPs) within a pathogen genome dataset, public health scientists can estimate the genetic identity between isolates. This information is used as an epidemiologic proxy of a putative outbreak. Pathogens with minimal to no differences in SNPs are likely to be the same strain attributable to a common source or transmission between cases. These genomic comparisons enhance public health response by prompting targeted intervention and infection control measures. This methodology overview demonstrates the utility of phenotypic and molecular assays, antimicrobial susceptibility testing (AST), NGS, publicly available genomics databases, and open-source bioinformatics pipelines for a tiered workflow to detect resistance genes and potential clusters of illness. These methods, when used in combination, facilitate a genomic surveillance workflow for detecting potential AMR bacterial outbreaks to inform epidemiologic investigations. Use of this workflow helps to target and focus epidemiologic resources to the cases with the highest likelihood of being related.

Keywords: antimicrobial resistance; carbapenem-resistant organisms; next-generation sequencing; outbreak; surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents*
  • Carbapenems* / pharmacology
  • Genome, Bacterial
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Phylogeny

Substances

  • Carbapenems
  • Anti-Infective Agents

Grants and funding

The work described herein was funded by the Centers for Disease Control and Prevention Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement with the National Center for Emerging and Zoonotic Infectious Diseases (5NU50CK000555-04-00).